IL6 and non-Hodgkin lymphoma: The same virtual population was also used to reproduce cytokine (IL6) dynamics observed in NHL patients receiving continuous infusion of blinatumomab in either a step-up dosing regimen (5 μg/m2/day for the 1st week, 15 μg/m2/day for the 2nd week, 60 μg/m2/day for the 3rd week) or a constant regimen of blinatumomab (60 μg/m2/day throughout)34.